Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 2/3 1

Status

Completed 5Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Post-operative Residual Curarization 1Brain Neoplasms 1

Interventions

Metformin 16Cyclophosphamide 16Drug Therapy 14Dexamethasone 14Cisplatin 13Cytarabine 11Gemcitabine 10Radiotherapy 9Oxaliplatin 9Carboplatin 9Vincristine 8Paclitaxel 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Sugammadex × Clear all
NCT05202899 2022-03-09

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Guangzhou General Hospital of Guangzhou Military Command

Phase 4 Unknown
40 enrolled
CNS

Brain Neoplasms

NCT03996655 2019-06-25

Different Reversal Agents in Pediatric Day-case Cancer Surgery

National Cancer Institute, Egypt

Phase 4 Unknown
80 enrolled

Post-operative Residual Curarization

Data powered by HemOnc (CC BY 4.0) Colophon âš¡